Neogene Therapeutics, Inc.: Neogene Therapeutics Announces Exclusive License with the National Cancer Institute for a Portfolio of T Cell Receptors (TCR) Targeting KRAS and TP53 Mutations for the Treatment of Cancer

Portfolio of TCRs developed in the laboratory of immunotherapy pioneer Steven Rosenberg, M.D., Ph.D. at the National Cancer Institute, combined with Neogene's proprietary TCR isolation platform, provides

Related Keywords

Carsten Linnemann ,Kostenloser Wertpapierhandel ,Steven Rosenberg ,Chan Lee ,Sheryl Seapy ,Neogene Therapeutics Inc ,National Cancer Institute ,National Institutes Of Health ,Healthcare Conference ,National Institutes ,Chief Medical Officer ,Chief Executive Officer ,Neogene Therapeutics ,Financial Officer ,Neogene ,Herapeutics ,Nnounces ,Exclusive ,License ,Ational ,Dancer ,Institute ,Portfolio ,Fell ,Receptors ,Targeting ,Ras ,Tp53 ,Mutations ,Treatment ,